natgillin/translations-raw huggingface dataset:
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Posebni previdnostni ukrepi za uporabo pri živalih:
In case of accidental self-ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo: V primeru nenamernega zaužitja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali ovojnino.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Bottle label -8 mg, 16 mg, 32 mg, 64 mg
Nalepka na plastenki 8 mg, 16 mg, 32 mg, 64 mg
Pack size of one bottle.
Pakiranje vsebuje eno plastenko.
Reconcile 8 mg chewable tablets for dogs Reconcile 16 mg chewable tablets for dogs Reconcile 32 mg chewable tablets for dogs Reconcile 64 mg chewable tablets for dogs fluoxetine
Reconcile 8 mg žvečljive tablete za pse Reconcile 16 mg žvečljive tablete za pse Reconcile 32 mg žvečljive tablete za pse Reconcile 64 mg žvečljive tablete za pse fluoksetin
Reconcile 8 mg chewable tablets for dogs Reconcile 16 mg chewable tablets for dogs Reconcile 32 mg chewable tablets for dogs Reconcile 64 mg chewable tablets for dogs
Reconcile 8 mg žvečljive tablete za pse Reconcile 16 mg žvečljive tablete za pse Reconcile 32 mg žvečljive tablete za pse Reconcile 64 mg žvečljive tablete za pse
Your doctor will check whether Paglitaz is working 3 to 6 months after you start taking it.
Zdravnik bo preveril, ali zdravilo Paglitaz deluje, 3 do 6 mesecev po tem, ko začnete jemati zdravilo.
Your blood sugar will be checked, and your dose of Paglitaz may need to be changed.
Preverili bodo raven vašega krvnega sladkorja in vaš odmerek zdravila Paglitaz bo morda potrebno spremeniti.
Paglitaz helps control the level of sugar in your blood when you have type 2 diabetes by helping your body make better use of the insulin it produces.
Zdravilo Paglitaz pomaga nadzorovati raven sladkorja v krvi, če imate sladkorno bolezen tipa 2, in sicer tako, da telesu pomaga bolje izkoristiti insulin, ki ga izdela.
Date of first authorisation: 21 March 2012 Date of latest renewal:
Datum prve odobritve: 21. marec 2012
What Paglitaz is and what it is used for
Kaj je zdravilo Paglitaz in za kaj ga uporabljamo
- This educational pack is aimed at strengthening awareness of important identified risks of bladder cancer and heart failure and the overall recommendations intended to optimise the benefit-risk margin at the patient level.
- Namen tega izobraževalnega paketa je povečati zavedanje o pomembnih znanih tveganjih za nastanek raka mehurja in srčnega popuščanja ter celokupna priporočila, namenjena optimizaciji meje med koristjo in tveganjem pri vsakem bolniku.
75 years old.
zlasti če ste starejši od 75 let.
If you take Paglitaz with other medicines for diabetes, it is more likely that your blood sugar could fall below the normal level (hypoglycaemia).
Če ste vzeli zdravilo Paglitaz z drugimi zdravili za zdravljenje sladkorne bolezni, je bolj verjetno, da vrednost vašega krvnega sladkorja pade pod normalno raven (hipoglikemija).
Paglitaz with food and drink You may take your tablets with or without food.
Zdravilo Paglitaz skupaj s hrano in pijačo Tablete lahko zaužijete s hrano ali brez nje.
You can usually continue to take other medicines whilst you are being treated with Paglitaz.
Običajno lahko še naprej jemljete druga zdravila, medtem ko se zdravite z zdravilom Paglitaz.
- if you have blood in your urine that your doctor has not checked.
- če imate ali ste imeli rak mehurja; - če imate kri v urinu, ki ga zdravnik ni preiskal.
When treating patients who have at least one risk factor for development of congestive heart failure (e.g. prior myocardial infarction or symptomatic coronary artery disease or the elderly), physicians should start with the lowest available dose and increase the dose gradually.
Pri zdravljenju bolnikov, ki imajo vsaj en dejavnik tveganja za razvoj kongestivnega srčnega popuščanja (npr. predhodni miokardni infarkt ali simptomatska koronarna arterijska bolezen ali starejši bolniki), bi moral zdravnik začeti zdravljenje z najnižjim možnim odmerkom in ga postopoma višati.
Before you start taking Paglitaz you will have a blood sample taken to check your liver function.
Pred začetkom jemanja zdravila Paglitaz vam bodo odvzeli vzorec krvi, da se preveri delovanje vaših jeter.
When Paglitaz is taken in combination with other medicines used to treat diabetes (such as insulin, chlorpropamide, glibenclamide, gliclazide, tolbutamide) your doctor will tell you whether you need to take a smaller dose of your medicines.
Če boste jemali zdravilo Paglitaz skupaj z drugimi zdravili za zdravljenje sladkorne bolezni (kot so insulin, klorpropamid, glibenklamid, gliklazid, tolbutamid), vam bo zdravnik povedal, ali morate jemati nižje odmerke teh zdravil.
- The physician educational pack should contain: The Summary of Product Characteristics, package leaflet, and a Prescriber Guide.
- Izobraževalni paket za zdravnika mora vsebovati: Povzetek glavnih značilnosti zdravila, navodilo za uporabo in priročnik za predpisovanje zdravila.
There may be an increased possibility of your becoming pregnant because you may ovulate again when you take Paglitaz.
Obstaja povečana možnost zanositve, ker lahko spet pride do ovulacije, ko ste vzeli zdravilo Paglitaz.
Take Paglitaz tablets daily as prescribed.
Zdravilo Paglitaz jemljite vsak dan, kakor vam je predpisano.
Tell your doctor or pharmacist if you are taking , have recently taken or might take any other medicines.
Obvestite zdravnika ali farmacevta, če jemljete , ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
Pioglitazone is indicated as second or third line in the treatment of type 2 diabetes mellitus as described below:
Zdravilna učinkovina pioglitazon je indicirana kot drugi ali tretji izbor zdravljenja sladkorne bolezni tipa 2, kot je opisano spodaj:
What you need to know before you take Paglitaz
Kaj morate vedeti, preden boste vzeli zdravilo Paglitaz
What Paglitaz is and what it is used for What you need to know before you take Paglitaz How to take Paglitaz
Kaj je zdravilo Paglitaz in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Paglitaz
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.Your doctor will advise you to discontinue this medicine.
Če ste noseči ali dojite, menite, da bi lahko bili noseči, ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden vzamete to zdravilo.
Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with Paglitaz and insulin experienced the development of heart failure.
Nekateri bolniki z dolgotrajno sladkorno boleznijo tipa 2 in srčno boleznijo ali predhodno kapjo, ki so bili zdravljeni z zdravilom Paglitaz in insulinom so doživeli razvoj srčnega popuščanja.
If you are following a diabetic diet, you should continue with this while you are taking Paglitaz.
Če ste na diabetični dieti, jo med jemanjem zdravila Paglitaz nadaljujte.
If you accidentally take too many Paglitaz tablets, or if someone else or a child takes your medicine, talk to a doctor or pharmacist immediately.
Če ste vzeli večji odmerek zdravila Paglitaz, kot bi smeli Če po nesreči zaužijete preveč tablet Paglitaz ali če kdo drug ali otrok zaužije vaša zdravila, nemudoma obvestite svojega zdravnika ali farmacevta.
Other medicines and Paglitaz
Druga zdravila in zdravilo Paglitaz
If you have the impression that the effect of Paglitaz is too weak, talk to your doctor.
Če menite, da je učinek zdravila Paglitaz prešibak, se posvetujte z zdravnikom.
If you stop taking Paglitaz
Če ste prenehali jemati zdravilo Paglitaz
If you forget to take Paglitaz
Če ste pozabili vzeti zdravilo Paglitaz
Paglitaz contains pioglitazone.
Zdravilo Paglitaz vsebuje pioglitazon.
Your doctor will ask you to have blood tests periodically during treatment with Paglitaz.
Zdravnik vas bo v času zdravljenja z zdravilom Paglitaz naročil na redne preiskave krvi.
as monotherapy - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;
kot monoterapija - pri odraslih bolnikih (predvsem bolnikih s prekomerno telesno maso), nezadostno nadzorovanih z dieto in gibanjem, pri katerih je metformin, zaradi kontraindikacij ali neprenašanja,
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE
A. IZDELOVALEC (IZDELOVALECI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ
Deutschland TAD Pharma GmbH Tel: + 49 (0) 4721 606-0
TAD Pharma GmbH Tel: + 49 (0) 4721 606-0
Talk to your doctor before taking Paglitaz: - if you retain water (fluid retention) or have heart failure problems in particular if you are over
Pred začetkom jemanja zdravila Paglitaz se posvetujte z zdravnikom - če zadržujete vodo (zastajanje tekočine v telesu) ali imate probleme s srčnim popuščanjem,
Although the study failed regarding its primary endpoint, which was a composite of all-cause mortality, non-fatal myocardial infarction, stroke, acute coronary syndrome, major leg amputation, coronary revascularisation and leg revascularisation, the results suggest that there are no long-term cardiovascular concerns regarding use of pioglitazone.
neusodnih miokardnih infarktov, kapi, akutnih koronarnih sindromov, težjih amputacij nog, koronarnih revaskularizacij in revaskularizacij nog, rezultati kažejo, da ni dolgoročnih kardiovaskularnih skrbi glede uporabe pioglitazona.
Combination with sulphonylurea with metformin and sulphonylurea with insulin
Kombinacija s sulfonilsečnino z metforminom in sulfonilsečnino z insulinom
Frequencies are defined as: - Very common ( 1/10) - Common ( 1/100 to < 1/10) - Uncommon ( 1/1,000 to < 1/100) - Rare ( 1/10,000 to < 1/1,000) - Very rare (< 1/10,000) - Not known (cannot be estimated from the available data)
Neželeni učinki, o katerih so poročali večkrat (> 0,5%) kot pri placebu in več kot enkrat pri bolnikih, ki so prejemali pioglitazon v dvojno slepih študijah, so našteti spodaj, in sicer po razredih organskih sistemov in absolutni pogostnosti, kot je priporočeno po MedDRA. Pogostnosti so določene kot: - zelo pogosti (≥ 1/10), - pogosti (≥ 1/100 do < 1/10), - občasni (≥ 1/1.000 do < 1/100), - redki (≥ 1/10.000 do < 1/1.000), - zelo redki (< 1/10.000), - neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Paglitaz tablets should be used every day to work properly.
Za pravilno delovanje je potrebno zdravilo Paglitaz jemati vsak dan.
Environmental Risk Assessment (ERA) : no environmental impact is anticipated from the clinical use of pioglitazone.
Ocena tveganja za okolje: ob klinični uporabi pioglitazona ni pričakovati vpliva na okolje.
The other side effects that have been experienced by some patients when Paglitaz is taken with other antidiabetic medicines are:
Pri nekaterih bolnikih, ki so jemali zdravilo Paglitaz skupaj z drugimi antidiabetičnimi zdravili, so se pojavili naslednji drugi neželeni učinki:
Bladder cancer has been experienced uncommonly (may affect up to 1 in 100 people) in patients taking Paglitaz.
Rak mehurja se lahko pojavi občasno (pojavijo se lahko pri največ 1 od 100 bolnikov) pri bolnikih, ki jemljejo zdravilo Paglitaz.
How to take Paglitaz
Kako jemati zdravilo Paglitaz
What Paglitaz contains - The active substance is pioglitazone.
Kaj vsebuje zdravilo Paglitaz - Zdravilna učinkovina je pioglitazon.
Allergic reactions have been reported (frequency not known) in patients taking Paglitaz.
Pri bolnikih, ki jemljejo zdravilo Paglitaz, so poročali o alergijskih reakcijah (pogostnost ni znana).
Heart failure has been experienced commonly (may affect up to 1 in 10 people) in patients taking Paglitaz in combination with insulin.
Odpoved srca je bila pogosto (pojavijo se lahko pri največ 1 od 10 bolnikov) ugotovljena pri bolnikih, ki so jemali Paglitaz v kombinaciji z insulinom.
Neoplasms benign, malignant and unspecified (including cysts and polyps) bladder cancer uncommon uncommon uncommon uncommon uncommon Respiratory, thoracic and mediastinal disorders dyspnoea common
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi) rak mehurja občasni občasni občasni
The risk of fractures should be considered in the long term care of patients treated with pioglitazone.
Pri dolgoročnem zdravljenju bolnikov s pioglitazonom je potrebno upoštevati tveganje za zlome.
as dual oral therapy in combination with - metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin; - a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;
- s sulfonilsečnino, le pri odraslih bolnikih, ki ne prenašajo metformina ali je metformin pri njih kontraindiciran, z nezadostnim nadzorom glikemije kljub najvišjemu toleriranemu odmerku kot trojno peroralno zdravljenje v kombinaciji: - z metforminom in s sulfonilsečnino pri odraslih bolnikih (predvsem bolnikih s prekomerno telesno maso) z nezadostnim nadzorom glikemije kljub dvojnemu peroralnemu zdravljenju.
Talk to your doctor before stopping this treatment.
Zdravnik vam bo svetoval, da prenehate z jemanjem tega zdravila.
Investigations weight increased common common common common common blood creatine phospho-kinase increased common increased lactic dehydro-genase uncommon
Preiskave povečanje telesne mase povišana vrednost kreatin fosfokinaze v krvi povišana vrednost laktatne dehidrogenaze občasni zvišana vrednost alaninaminotransferaze neznana neznana neznana
Paglitaz may be used on its own in patients who are unable to take metformin, and where treatment with diet and exercise has failed to control blood sugar or may be added to other therapies (such as metformin, sulphonylurea or insulin) which have failed to provide sufficient control in blood sugar.
Zdravilo Paglitaz lahko uporabljamo samo pri bolnikih, ki ne morejo jemati metformina, in ko zdravljenje z dieto in telesno vadbo ni uspešno pri nadzoru krvnega sladkorja.
Blurred vision due to swelling (or fluid) at the back of the eye (frequency not known) has also been reported in patients taking Paglitaz.
Bolniki, ki so jemali Paglitaz, so poročali tudi o zamegljenem vidu zaradi otekanja (ali tekočine) očesnega ozadja (pogostnost ni poznana).
Combination with metformin with sulphonylurea with metformin and sulphonylurea with insulin oedema very common fatigue uncommon
Kombinacija z metforminom s sulfonilsečnino z metforminom in sulfonilsečnino z insulinom edem zelo pogosti utrujenost občasni
as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.
kot dvojno peroralno zdravljenje v kombinaciji: - z metforminom pri odraslih bolnikih (predvsem bolnikih s prekomerno telesno maso) z nezadostnim nadzorom glikemije kljub najvišjemu toleriranemu odmerku monoterapije z
The other side effects that have been experienced by some patients taking Paglitaz are:
Pri nekaterih bolnikih, ki so jemali zdravilo Paglitaz, so se pojavili drugi neželeni učinki:
What Paglitaz looks like and contents of the pack White to almost white round tablets with bevelled edges (diameter 8.0 mm).
Izgled zdravila Paglitaz in vsebina pakiranja Bele do skoraj bele, okrogle tablete s prirezanimi robovi (premer 8,0 mm).
14 tablets: EU/1/11/721/001 28 tablets: EU/1/11/721/002 30 tablets: EU/1/11/721/003 56 tablets: EU/1/11/721/004 60 tablets: EU/1/11/721/005 90 tablets: EU/1/11/721/006 98 tablets: EU/1/11/721/007
14 tablet: EU/1/11/721/001 28 tablet: EU/1/11/721/002 30 tablet: EU/1/11/721/003 56 tablet: EU/1/11/721/004 60 tablet: EU/1/11/721/005 90 tablet: EU/1/11/721/006 98 tablet: EU/1/11/721/007
14 tablets: EU/1/11/721/015 28 tablets: EU/1/11/721/016 30 tablets: EU/1/11/721/017 56 tablets: EU/1/11/721/018 60 tablets: EU/1/11/721/019 90 tablets: EU/1/11/721/020 98 tablets: EU/1/11/721/021
14 tablet: EU/1/11/721/015 28 tablet: EU/1/11/721/016 30 tablet: EU/1/11/721/017 56 tablet: EU/1/11/721/018 60 tablet: EU/1/11/721/019 90 tablet: EU/1/11/721/020 98 tablet: EU/1/11/721/021
14 tablets: EU/1/11/721/008 28 tablets: EU/1/11/721/009 30 tablets: EU/1/11/721/010 56 tablets: EU/1/11/721/011 60 tablets: EU/1/11/721/012 90 tablets: EU/1/11/721/013 98 tablets: EU/1/11/721/014
14 tablet: EU/1/11/721/008 28 tablet: EU/1/11/721/009 30 tablet: EU/1/11/721/010 56 tablet: EU/1/11/721/011 60 tablet: EU/1/11/721/012 90 tablet: EU/1/11/721/013 98 tablet: EU/1/11/721/014
What Paglitaz looks like and contents of the pack White to almost white round tablets with bevelled edges and with engraved "45" on one side of tablet (diameter 10.0 mm).
Izgled zdravila Paglitaz in vsebina pakiranja Bele do skoraj bele, okrogle tablete s prirezanimi robovi in z oznako ‘45' na eni strani (premer 10,0 mm).
What Paglitaz looks like and contents of the pack White to almost white round tablets with bevelled edges and with engraved "15" on one side of tablet (diameter 7.0 mm).
Izgled zdravila Paglitaz in vsebina pakiranja Bele do skoraj bele, okrogle tablete s prirezanimi robovi in z oznako ‘15' na eni strani (premer 7,0 mm).
How to store Paglitaz
Shranjevanje zdravila Paglitaz
Paglitaz tablets contain lactose monohydrate and therefore should not be administered to patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
- if you have a special type of diabetic eye disease called macular oedema (swelling of the back of the eye).
Če jemljete protivnetna zdravila, ki tudi lahko povzročijo zastajanje tekočine v telesu in otekanje, morate o tem prav tako obvestiti svojega zdravnika; - če imate poseben tip diabetične očesne bolezni, imenovane makularni edem (oteklina očesnega ozadja);
Alanine aminotransferase increased not known not known not known not known not known
Očesne bolezni motnje vida občasni makularni edem neznana neznana neznana neznana neznana
Localised swelling (oedema) has also been experienced very commonly in patients taking Paglitaz in combination with insulin.
Pri bolnikih, ki so jemali Paglitaz v kombinaciji z insulinom, je bilo zelo pogosto ugotovljeno lokalno otekanje (edemi).
If you experience this symptom for the first time, talk to your
Če ste prvič opazili ta simptom, se posvetujte s svojim zdravnikom kakor hitro mogoče.
Paglitaz contains lactose monohydrate
Zdravilo Paglitaz vsebuje laktozo.
If you stop using Paglitaz tablets, your blood sugar may go up.
Če ste prenehali jemati zdravilo Paglitaz, se vam lahko raven krvnega sladkorja zviša, zato se posvetujte z zdravnikom, preden prenehate s tem zdravljenjem.
If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking Paglitaz.
Zdravilo Paglitaz vsebuje laktozo monohidrat Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se pred uporabo tega zdravila posvetujte s svojim zdravnikom.
Do not take Paglitaz: - if you are hypersensitive (allergic) to pioglitazone or any of the other ingredients of this medicine (listed in section 6).
Pioglitazon je kontraindiciran pri bolnikih: - s preobčutljivostjo na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju
Broken bones have been reported commonly (may affect up to 1 in 10 people) in women patients taking Paglitaz.
Pri bolnicah, ki so jemale Paglitaz, je bil pogosto (pojavljajo se lahko pri največ 1 od 10 bolnic) opažen zlom kosti.
These or other signs may mean the person might need treatment in hospital.
Ti ali drugi znaki lahko pomenijo, da oseba potrebuje zdravljenje v bolnišnici.
However, you should seek immediate treatment in any event.
Vendar morate takojšnje zdravljenje poiskati v vsakem primeru.
Most people fully recover from the illness.
Večina ljudi si od bolezni povsem opomore.
Date of first authorisation: 02 February 2005 Date of latest renewal: 10 December 2009
Datum pridobitve dovoljenja za promet: 02. februar 2005 Datum zadnjega podaljšanja dovoljenja za promet: 10. december 2009
Such reactions may occur before leaving the doctor's surgery.
Takšne reakcij se lahko pojavijo, še preden zapustite zdravnikovo ordinacijo.
• This means they can still infect other people and are known as virus “carriers”.
• To pomeni, da še vedno lahko okužijo druge in jih imenujemo "nosilci virusa".
If this happens, take special care while driving or using any tools or machines.
Če se vam to zgodi, bodite posebno pozorni pri vožnji in uporabi orodij ali strojev.
If not, you may not be fully protected against the disease.
V nasprotnem primeru je možno, da pred boleznijo niste popolnoma zaščiteni.
Your doctor will make sure that the vaccines are injected into different parts of the body.
Zdravnik bo poskrbel, da vam bodo cepivi injicirali v različne dele telesa.
• The hepatitis B virus stays in the body of some people all through their lives.
• Virus hepatitisa B ostane v telesu nekaterih ljudi vse njihovo življenje.
• Signs may not be seen for 6 weeks to 6 months after infection.
• Znaki se lahko pojavijo šele 6 tednov do 6 mesecev po okužbi.
These antibodies will protect you against the disease.
Ta protitelesa vas bodo ščitila pred boleznijo.
A minor infection such as a cold should not be a problem, but talk to your doctor first.
Blažja okužba, npr. prehlad, ne bi smela biti težava, vendar se vseeno najprej pogovorite z zdravnikom.
• Some people with hepatitis B do not look or feel ill - they do not have any signs of illness.
• Nekatere osebe s hepatitisom B niso videti bolne in se ne počutijo bolne - takšne osebe nimajo nobenih znakov bolezni.
The vaccine can be given after you have recovered.
Cepivo lahko dobite, ko okrevate.
Their frequency is defined using the conventions listed below:
Njihova pogostnost je opredeljena upoštevaje spodaj navedeni dogovor:
• loss of feeling or problems moving some parts of your body
• izguba občutka ali težave s premikanjem nekaterih delov telesa,
However, solicited general symptoms were observed with similar frequencies in both groups.
Splošni spontani simptomi so bili opaženi s podobno pogostnostjo v obeh skupinah.
• infection caused by a virus
• okužba, ki jo povzroči virus,
• The doctor or nurse will tell you when you should come back for the next injections.
• Zdravnik ali medicinska sestra vam bosta povedala, kdaj morate priti po naslednje injekcije.
Read all of this leaflet carefully before you receive this vaccine because it contains important information for you.
Preden prejmete to cepivo, natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
What is hepatitis B?
Kaj je hepatitis B?
• allergic reactions, including anaphylactoid reactions.
• alergijske reakcije, vključno z anafilaktoidnimi reakcijami.
Your doctor will tell you if you need any extra or “booster” injections in the future.
Zdravnik vam po povedal, ali v prihodnosti potrebujete kakšne dodatne ali 'obnovitvene' injekcije.
Limited data on overdose are available.
Na voljo so omejeni podatki o prevelikem odmerjanju.
The doctor or nurse will give Fendrix as an injection into your muscle.
Zdravnik ali medicinska sestra vam bosta dala cepivo Fendrix kot injekcijo v mišico.
The safety and efficacy of Fendrix in children aged less than 15 years have not been established.
Učinkovitost in varnost cepiva Fendrix nista ugotovljeni pri otrocih, mlajših od 15 let.
• You will have a series of four injections.
• Prejeli boste zaporedje štirih injekcij.
• problems with the nerves of your eye (optic neuritis)
• težave z očesnim živcem (optični nevritis),
• Store in a refrigerator (2°C - 8°C).
• Shranjujte v hladilniku (2°C - 8°C).